Hirano H, Takahashi N, Amanuma Y, Suzuki N, et al. Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE) BMC Cancer 2025;25:201.
PMID: 39905373